Figure 2.

Response to repeated contralateral bevacizumab injections in a 62-year-old male with bilateral diabetic macular edema. Initial central subfield thickness (top row) was 446 μm in the right eye and 327 μm in the left eye. LogMar BCVA was 0.32 (Snellen equivalent 20/42) in both eyes. Five bevacizumab injections were given to his left eye during 10 months while the right remained untreated. Iterative injections were requested before a clinical effect was observed (no substantial response recorded in either eye after the first injection, second row). At the end of follow-up (third row), macular thickness reduced to 318 μm (−9 μm, −2.8%) in the left injected eye and to 335 μm (−111 μm, −24.9%) in the right non-injected eye. LogMar BCVA remained 0.32 (Snellen equivalent 20/42) in the injected eye but improved to 0.22 (Snellen equivalent 20/33) in the non-injected eye.